Nextgen Bioscience Co. Ltd. describes new compounds acting as hypoxia inducible factor-1α (HIF-1α) or vascular endothelial growth factor receptor (VEGFR) inhibitors and reported to be useful for the treatment of stroke, cancer, obesity, asthma, glaucoma, inflammatory bowel disease, rheumatoid arthritis and Alzheimer’s disease, among others.